期刊文献+

低氧诱导因子在肿瘤治疗中的研究进展 被引量:2

Advance of the tumor therapy based on hypoxia-inducing factor inhibitors
下载PDF
导出
摘要 低氧诱导因子(HIF)是恶性肿瘤适应低氧微环境的关键因子,已成为恶性肿瘤抑制剂及基因治疗研究的重要靶点,本文综述其在肿瘤抑制剂治疗中的研究进展。 Hypoxia-inducible factor(HIF) plays a key role in the adaptation of tumour cells under hypoxic circumstance, there are some advances in the literatures regarding HIF as an important target for anticancer agents and gene therapy, In this review, the molecular mechanism and clinical significance of compounds targeting on hypoxiainducing factor was summarized.
出处 《中国癌症杂志》 CAS CSCD 2008年第11期866-869,共4页 China Oncology
基金 国家自然科学基金资助项目(No.30660192) 江西省研究生创新基金(No.YC07A018)
关键词 低氧 肿瘤 治疗 抑制剂 hypoxia neoplasms therapy inhibitor
  • 相关文献

参考文献33

  • 1Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular Oz tension [ J ] . Proc Natl Acad Sci USA, 1995,92(12) :5510-5514
  • 2Semenza GL. Targeting HIF-1 for cancer therapy [ J]. Nat Rev Cancer, 2003,3(10):721-732.
  • 3Kurebayashi J, Otsuki T, Kurosumi M, et al. A radicicol derivative, KF58333, inhibits expression of hypnxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts [ J ] . Jpn J Cancer Res, 2001,92(12):1342-1351.
  • 4Welsh S J, Williams RR, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation [ J ] . Mol Cancer Ther, 2003,2(3):235-243.
  • 5Cohen-Jonathan E, Evans SM, Koch C J, et al. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras [J ]. Cancer Res, 2001,61(5):2289-2293.
  • 6Blum R, Jacob-Hirsch J, Amariglio N, et al. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor- 1alpha, causing glycolysis shut down and cell death [ J ] . Cancer Res, 2005,65(3):999-1006.
  • 7Tan C, de Noronha RG, Roeeker AJ, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway [ J ]. Cancer Res, 2005, 65(2):605-612.
  • 8Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model [ J ] . Int J Cancer, 2007, 120(8):1803-1810.
  • 9Guba M, yon Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor [ J ] . Nat Med, 2002,8(2):128-135.
  • 10Liu M, Howes A, Lesperanee J, et al. Antitumor activity of rapamycin in a transgenie mouse model of ErhB2-dependent human breast cancer [ J ]. C Res, 2005,65(12):5325- 5336

二级参考文献11

  • 1周俭,樊嘉,吴志全,邱双健,王征,黄晓武,余耀,贺轶锋,汤钊猷,王玉琦.单中心连续203例肝移植临床疗效分析[J].中华医学杂志,2005,85(26):1805-1808. 被引量:13
  • 2Sun FX,Tang ZY,Liu KD,et al.Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues.Int J Cancer,1996,66:239 -243.
  • 3Hale DA,Gottschalk R,Maki T,et al.Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.Transplantation,1997,64:897-900.
  • 4Chen H,Qi S,Xu D,et al.FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse.Transplant Proc,1998,30:1039-1041.
  • 5Mahalati K,Kahan BD.Clinical pharmacokinetics of sirolimus.Clin Pharmacokinet,2001,40:573-585.
  • 6Hashemolhosseini S,Nagamine Y,Morley SJ,et al.Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability.J Biol Chem,1998,273:14424-14429.
  • 7Castedo M,Ferri KF,Kroemer G.Mammalian target of rapamycin (mTOR):pro-and anti-apoptotic.Cell Death Differ,2002,9:99-100.
  • 8Guba M,von Breitenbuch P,Steinbauer M,et al.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor.Nat Med,2002,8:128-135.
  • 9Blancher C,Moore JW,Robertson N,et al.Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha,HIF-2alpha,and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.Cancer Res,2001,61:7349-7355.
  • 10Hojo M,Morimoto T,Maluccio M,et al.Cyclosporine induces cancer progression by a cell-autonomous mechanism.Nature,1999,397:530-534.

共引文献7

同被引文献30

  • 1杨洁,李占亭,杜德伟,柴青焕,王丽,张惠中,孙脊峰.缺氧调控报告载体的构建与鉴定[J].第四军医大学学报,2006,27(7):590-592. 被引量:3
  • 2曾东风,孔佩艳,陈幸华,张曦,常城,梁雪,高蕾.缺氧诱导因子-1α和PTEN、P53在急性髓性白血病骨髓基质细胞中的表达及意义[J].免疫学杂志,2007,23(3):316-318. 被引量:6
  • 3张博,翁勤洁,陈中婷,姜发琴,盛荣,胡永洲,何俏军,杨波.Q39在缺氧条件下诱导人白血病K562细胞凋亡[J].浙江大学学报(医学版),2007,36(3):261-266. 被引量:5
  • 4O'Donnell JL, Joyce MR, Shannon AM, et al. Oncologicalimplications of hypoxia inducible factor-lalpha (HIF-lalpha) expression[J]. Cancer Treat Rev, 2006, 32(6): 407-16.
  • 5Harris AL. Hypoxia-a key regulatory factor in tumour growth [J]. Nat Rev Cancer, 2002, 2(1): 38-47.
  • 6Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation [J]. Mol Cell Biol, 1992, 12(12): 5447-54.
  • 7Zhu H, Bunn HF. Oxygen sensing and signaling: impact on the regulation of physiologically important genes [J]. Respir Physiol, 1999, 115(2): 239-47.
  • 8陈国强,赵倩,黄鸳.HIF-1a在治疗白血病药物的筛选中的应用[P].中国,03150827.82003-09-05.
  • 9Jiang Y, Xue ZH, Shen WZ, et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/ enhancer-binding protein-alpha[J]. Leukemia, 2005, 19(7): 1239-47.
  • 10Xue ZH, Jiang Y, Yu Y, et al. Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-lalpha protein[J]. Biochem Biophys Res Commun, 2005, 332(4): 1140-5.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部